You are here: News TO ALL MARKET AUTHORIZATION HOLDERS

TO ALL MARKET AUTHORIZATION HOLDERS

TO ALL MARKET AUTHORIZATION HOLDERS

As per decision taken by the Medicines Evaluation sub-Committee of NMRA held on 24.01.2017 priority registration will be granted to the following Medicines.

1. AREPITANT

2. USTEKINUMAB


 

 

CEO-NMRA